Paper41312948
Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway.
Ahmed AA. Asian Pac J Cancer Prev, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway. Papers, record 41312948. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41312948
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Uterine Cervical Neoplasms | Major topic |
| Epithelial-Mesenchymal Transition | Major topic |
| Ciprofloxacin | Major topic |
| Rivaroxaban | Major topic |
| Drug Repositioning | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| Female | |
| Drug Synergism | |
| Molecular Docking Simulation | |
| Cell Movement | |
| Cell Proliferation | |
| Tumor Cells, Cultured |
Source PubMed
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27683123 | The changing 50% inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer. | Oncotarget | 2016 | https://conductscience.org/library/papers/27683123 | PubMed |
| 2 | 38680005 | The Cytotoxic Effect of Ciprofloxacin Laetrile Combination on Esophageal Cancer Cell Line. | Asian Pac J Cancer Prev | 2024 | https://conductscience.org/library/papers/38680005 | PubMed |
| 3 | 39598770 | Unveiling the Anticancer Potential of a New Ciprofloxacin-Chalcone Hybrid as an Inhibitor of Topoisomerases I & II and Apoptotic Inducer. | Molecules | 2024 | https://conductscience.org/library/papers/39598770 | PubMed |
| 4 | 28112728 | Integrated genomic and molecular characterization of cervical cancer. | Nature | 2017 | https://conductscience.org/library/papers/28112728 | PubMed |
| 5 | 38403630 | Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis. | World J Surg Oncol | 2024 | https://conductscience.org/library/papers/38403630 | PubMed |
| 6 | 39551860 | Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer. | NPJ Precis Oncol | 2024 | https://conductscience.org/library/papers/39551860 | PubMed |
| 7 | 38432579 | Effects of andiroba oil (Carapa guianensis aublet) on the immune system in inflammation and wound healing: A scoping review. | J Ethnopharmacol | 2024 | https://conductscience.org/library/papers/38432579 | PubMed |
| 8 | 36551965 | The Association of CD8+ Cytotoxic T Cells and Granzyme B+ Lymphocytes with Immunosuppressive Factors, Tumor Stage and Prognosis in Cutaneous Melanoma. | Biomedicines | 2022 | https://conductscience.org/library/papers/36551965 | PubMed |
| 9 | 35839811 | Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. | Lancet Glob Health | 2022 | https://conductscience.org/library/papers/35839811 | PubMed |
| 10 | 30044205 | 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation. | J Biomol Struct Dyn | 2019 | https://conductscience.org/library/papers/30044205 | PubMed |
| 11 | 32523090 | First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor. | Br J Cancer | 2020 | https://conductscience.org/library/papers/32523090 | PubMed |
| 12 | 33143025 | Recent Advances in Molecular Docking for the Research and Discovery of Potential Marine Drugs. | Mar Drugs | 2020 | https://conductscience.org/library/papers/33143025 | PubMed |
| 13 | 32397419 | Repurposing Cancer Drugs Batimastat and Marimastat to Inhibit the Activity of a Group I Metalloprotease from the Venom of the Western Diamondback Rattlesnake, Crotalus atrox. | Toxins (Basel) | 2020 | https://conductscience.org/library/papers/32397419 | PubMed |
| 14 | 28954413 | Current Development Status of MEK Inhibitors. | Molecules | 2017 | https://conductscience.org/library/papers/28954413 | PubMed |
| 15 | 35008569 | Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/35008569 | PubMed |
| 16 | 40302088 | Scrutiny of the Co-Cytotoxic Impact of Metformin-Omeprazole on the Cervical Cancer Cell Line and Their Aptitude to Target Heat Shock 60. | Asian Pac J Cancer Prev | 2025 | https://conductscience.org/library/papers/40302088 | PubMed |
| 17 | 36770806 | In Vitro Anticancer Activity of Novel Ciprofloxacin Mannich Base in Lung Adenocarcinoma and High-Grade Serous Ovarian Cancer Cell Lines via Attenuating MAPK Signaling Pathway. | Molecules | 2023 | https://conductscience.org/library/papers/36770806 | PubMed |
| 18 | 37313143 | Targeting Wnt/β-catenin signaling using XAV939 nanoparticles in tumor microenvironment-conditioned macrophages promote immunogenicity. | Heliyon | 2023 | https://conductscience.org/library/papers/37313143 | PubMed |
| 19 | 31791552 | A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. | Gynecol Oncol | 2020 | https://conductscience.org/library/papers/31791552 | PubMed |
| 20 | 32955176 | KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32955176 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TNKS | 8658 | PubTator's text mining | https://conductscience.org/library/genes/8658 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41312948
GET https://conductscience.org/api/papers/v1/41312948/references?page=2